15% below the list price of Lantus. The companies also hope to steal market share from Novo Nordisk, undercutting the long-acting Levemir (insulin detemir) by 21% and Tresiba (insulin degludec ...
Levemir (insulin detemir) has a shorter duration of action than other long-acting basal insulins like Sanofi's Lantus (insulin glargine) and biosimilars and Novo Nordisk's newer product Tresiba ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback